Injectable Semaglutide (Wegovy) Clinical trials showed approximately 15 percent average weight loss over 68 weeks compared with placebo
The FDA has approved several GLP-1 medications including liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound)though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
The honest answer, though, is a little more complicated than a simple yes
Demand information, lay out why you think this drug is right for you, and if your provider says no, ask for an explanation. An individualized discussion with your healthcare provider is the best way to determine which medication may be right for you, Dutta said
Mostly regulatory and marketing reasons
Zuckerman MD, Boyle KL, Rosenbaum CD